• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response.通过减少未折叠蛋白反应的结合来增强凝血因子 VIII 的生物合成。
J Biol Chem. 2011 Jul 8;286(27):24451-7. doi: 10.1074/jbc.M111.238758. Epub 2011 May 23.
2
Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.共聚焦显微镜分析天然、全长及B结构域缺失的凝血因子VIII在哺乳动物细胞中的运输。
Thromb Haemost. 2004 Jul;92(1):23-35. doi: 10.1160/TH03-06-0360.
3
Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.用于提高血友病 A 基因治疗中表达的改良因子 VIII 转基因的比较。
Hum Gene Ther. 2009 May;20(5):465-78. doi: 10.1089/hum.2008.150.
4
Blood coagulation factor VIII D1241E polymorphism leads to a weak malectin interaction and reduction of factor VIII posttranslational modification and secretion.凝血因子VIII D1241E多态性导致与麦芽凝集素的相互作用减弱,并降低凝血因子VIII的翻译后修饰和分泌。
Exp Cell Res. 2020 Dec 1;397(1):112334. doi: 10.1016/j.yexcr.2020.112334. Epub 2020 Nov 2.
5
Development and characterization of recombinant ovine coagulation factor VIII.重组绵羊凝血因子 VIII 的开发和特性研究。
PLoS One. 2012;7(11):e49481. doi: 10.1371/journal.pone.0049481. Epub 2012 Nov 9.
6
Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII.具有保留功能活性的 VIII 因子-eGFP 融合蛋白,用于分析 VIII 因子的早期分泌途径。
Thromb Haemost. 2009 Nov;102(5):925-35. doi: 10.1160/TH08-12-0807.
7
Expression of human coagulation factor VIII in a human hybrid cell line, HKB11.人凝血因子VIII在人杂交细胞系HKB11中的表达。
Mol Biotechnol. 2006 Oct;34(2):165-78. doi: 10.1385/MB:34:2:165.
8
Functional Coupling between the Unfolded Protein Response and Endoplasmic Reticulum/Golgi Ca-ATPases Promotes Stress Tolerance, Cell Wall Biosynthesis, and Virulence of Aspergillus fumigatus. unfolded protein response 与内质网/高尔基体 Ca-ATPases 之间的功能偶联促进烟曲霉的应激耐受、细胞壁生物合成和毒力。
mBio. 2020 Jun 2;11(3):e01060-20. doi: 10.1128/mBio.01060-20.
9
Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII.LMAN1 和 MCFD2 在 FV 和 FVIII 的内质网到高尔基体运输中的不同作用。
Blood Adv. 2023 Apr 11;7(7):1286-1296. doi: 10.1182/bloodadvances.2022008788.
10
[Enhancing effect of porcine coagulation factor VIII A1 and A3 domains on secretion of post-translationally spliced human/porcine hybrid coagulation factor VIII].[猪凝血因子VIII A1和A3结构域对翻译后剪接的人/猪杂交凝血因子VIII分泌的增强作用]
Sheng Li Xue Bao. 2010 Aug 25;62(4):373-81.

引用本文的文献

1
Hemophilia A: An Ideal Disease for Prenatal Therapy.甲型血友病:产前治疗的理想疾病。
Prenat Diagn. 2025 Jun 10. doi: 10.1002/pd.6833.
2
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.TAK-754的临床前开发,TAK-754是一种基于腺相关病毒8型(AAV8)的高效载体,可表达凝血因子VIII。
Mol Ther Methods Clin Dev. 2025 Jan 28;33(1):101424. doi: 10.1016/j.omtm.2025.101424. eCollection 2025 Mar 13.
3
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.采用CD34+造血细胞的慢病毒基因疗法治疗甲型血友病
N Engl J Med. 2025 Jan 30;392(5):450-457. doi: 10.1056/NEJMoa2410597. Epub 2024 Dec 9.
4
Cellular stress and coagulation factor production: when more is not necessarily better.细胞应激与凝血因子生成:过犹不及。
J Thromb Haemost. 2023 Dec;21(12):3329-3341. doi: 10.1016/j.jtha.2023.10.005. Epub 2023 Oct 14.
5
Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII.比较不同的基因添加策略,以修饰胎盘来源的间充质基质细胞来产生 FVIII。
Front Immunol. 2022 Dec 15;13:954984. doi: 10.3389/fimmu.2022.954984. eCollection 2022.
6
Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.药代动力学分析确定了 AAV 基因治疗血友病 A 小鼠后因子 VIII 免疫原性的阈值。
Blood Adv. 2022 Apr 26;6(8):2628-2645. doi: 10.1182/bloodadvances.2021006359.
7
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.血友病 A 的 AAV 基因转移后多年的因子 VIII 表达。
N Engl J Med. 2021 Nov 18;385(21):1961-1973. doi: 10.1056/NEJMoa2104205.
8
Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.探索用于产前或围产期递送因子VIII以治疗A型血友病的最佳自体细胞平台。
Front Cell Dev Biol. 2021 Aug 10;9:678117. doi: 10.3389/fcell.2021.678117. eCollection 2021.
9
Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII.非基因毒性预处理有助于利用生物工程因子VIII对A型血友病进行造血干细胞基因治疗。
Mol Ther Methods Clin Dev. 2021 May 5;21:710-727. doi: 10.1016/j.omtm.2021.04.016. eCollection 2021 Jun 11.
10
Molecular coevolution of coagulation factor VIII and von Willebrand factor.凝血因子 VIII 和血管性血友病因子的分子协同进化。
Blood Adv. 2021 Feb 9;5(3):812-822. doi: 10.1182/bloodadvances.2020002971.

本文引用的文献

1
Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.慢病毒载体平台生产生物工程重组凝血因子 VIII。
Mol Ther. 2011 Feb;19(2):302-9. doi: 10.1038/mt.2010.239. Epub 2010 Nov 16.
2
Haemophilia A and von Willebrand's disease.血友病 A 和血管性血友病。
Haemophilia. 2010 Jul;16 Suppl 5:79-84. doi: 10.1111/j.1365-2516.2010.02303.x.
3
Advancements in gene transfer-based therapy for hemophilia A.基于基因转移的甲型血友病治疗进展。
Expert Rev Hematol. 2009 Dec;2(6):673-683. doi: 10.1586/EHM.09.63.
4
Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.经基因修饰的造血干细胞移植治疗血友病 A 后因子 VIII 表达的功能方面。
J Gene Med. 2010 Apr;12(4):333-44. doi: 10.1002/jgm.1442.
5
Combined Factor V and Factor VIII Deficiency.联合因子V和因子VIII缺乏症。
Semin Thromb Hemost. 2009 Jun;35(4):390-9. doi: 10.1055/s-0029-1225761. Epub 2009 Jul 13.
6
Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.定向工程改造高表达嵌合转基因作为A型血友病基因治疗的一种策略。
Mol Ther. 2009 Jul;17(7):1145-54. doi: 10.1038/mt.2009.35. Epub 2009 Mar 3.
7
Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.用于提高血友病 A 基因治疗中表达的改良因子 VIII 转基因的比较。
Hum Gene Ther. 2009 May;20(5):465-78. doi: 10.1089/hum.2008.150.
8
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion.抗氧化剂可减轻内质网应激并改善蛋白质分泌。
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18525-30. doi: 10.1073/pnas.0809677105. Epub 2008 Nov 14.
9
The endoplasmic reticulum stress response in immunity and autoimmunity.内质网应激反应在免疫和自身免疫中的作用
Nat Rev Immunol. 2008 Sep;8(9):663-74. doi: 10.1038/nri2359.
10
Unconventional splicing of XBP-1 mRNA in the unfolded protein response.未折叠蛋白反应中XBP-1 mRNA的非常规剪接
Antioxid Redox Signal. 2007 Dec;9(12):2323-33. doi: 10.1089/ars.2007.1800.

通过减少未折叠蛋白反应的结合来增强凝血因子 VIII 的生物合成。

Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response.

机构信息

Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, USA.

出版信息

J Biol Chem. 2011 Jul 8;286(27):24451-7. doi: 10.1074/jbc.M111.238758. Epub 2011 May 23.

DOI:10.1074/jbc.M111.238758
PMID:21606503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3129224/
Abstract

Human and porcine coagulation factor VIII (fVIII) display a biosynthetic efficiency differential that is being exploited for the development of new protein and gene transfer-based therapies for hemophilia A. The cellular and/or molecular mechanism(s) responsible for this phenomenon have yet to be uncovered, although it has been temporally localized to post-translational biosynthetic steps. The unfolded protein response (UPR) is a cellular adaptation to structurally distinct (e.g. misfolded) or excess protein in the endoplasmic reticulum and is known to be induced by heterologous expression of recombinant human fVIII. Therefore, it is plausible that the biosynthetic differential between human and porcine fVIII results from differential UPR activation. In the current study, UPR induction was examined in the context of ongoing fVIII expression. UPR activation was greater during human fVIII expression when compared with porcine fVIII expression as determined by ER response element (ERSE)-luciferase reporter activity, X-box-binding protein 1 (XBP1) splicing, and immunoglobulin-binding protein (BiP) up-regulation. Immunofluorescence microscopy of fVIII expressing cells revealed that human fVIII was notably absent in the Golgi apparatus, confirming that endoplasmic reticulum to Golgi transport is rate-limiting. In contrast, a significant proportion of porcine fVIII was localized to the Golgi indicating efficient transit through the secretory pathway. Overexpression of BiP, an integral UPR protein, reduced the secretion of human fVIII by 50%, but had no effect on porcine fVIII biosynthesis. In contrast, expression of BiP shRNA increased human fVIII expression levels. The current data support the model of differential engagement of UPR by human and porcine fVIII as a non-traditional mechanism for regulation of gene product biosynthesis.

摘要

人和猪凝血因子 VIII(fVIII)显示出生物合成效率的差异,这一差异正被用于开发新型蛋白质和基因转移治疗血友病 A 的方法。尽管该现象已被暂时定位到翻译后生物合成步骤,但负责这一现象的细胞和/或分子机制尚未被揭示。未折叠蛋白反应(UPR)是细胞对内质网中结构不同(例如错误折叠)或过量蛋白的适应机制,已知其会被重组人 fVIII 的异源表达所诱导。因此,推测人 fVIII 和猪 fVIII 之间的生物合成差异是由于 UPR 激活的差异所致。在本研究中,在持续表达 fVIII 的背景下研究了 UPR 的诱导。通过 ER 反应元件(ERSE)-荧光素酶报告活性、X 框结合蛋白 1(XBP1)剪接和免疫球蛋白结合蛋白(BiP)的上调,发现人 fVIII 表达时 UPR 的激活比猪 fVIII 表达时更大。表达 fVIII 的细胞的免疫荧光显微镜检查显示,人 fVIII 在高尔基器中明显缺失,这证实了内质网到高尔基体的运输是限速的。相比之下,相当一部分猪 fVIII 被定位到高尔基,表明其穿过分泌途径的效率很高。BiP 的过表达(一种完整的 UPR 蛋白)将人 fVIII 的分泌减少了 50%,但对猪 fVIII 的生物合成没有影响。相反,BiP shRNA 的表达增加了人 fVIII 的表达水平。目前的数据支持人 fVIII 和猪 fVIII 通过 UPR 进行差异结合的模型,这是调节基因产物生物合成的一种非传统机制。